Mr. Nicholas Kadysh reports

PHARMALA TO SUPPLY OSTFOLD HOSPITAL TRUST WITH LANEO(TM) MDMA FOR CLINICAL RESEARCH

Pharmala Biotech Holdings Inc. has executed an agreement with Ostfold Hospital Trust of Norway.

"It was gratifying to be selected as the supplier to Ostfold Hospital Trust following a lengthy diligence and negotiation process completed over the summer and fall of 2025. We continue to be incredibly impressed with the team's success in both executing and publishing exceptional research into MDMA as a potential treatment for major depressive disorder," said Nicholas Kadysh, chief executive officer, Pharmala Biotech. "We are excited and committed to help support them in their goal and look forward to delivering investigational LaNeo MDMA to them to help support this exceptional work -- and gratified that our previous establishment of a value chain across Europe will be helpful in the technical operations needed to make this delivery."

The sales agreement contains both financial and data-sharing provisions. Pharmala will seek to ship its LaNeo MDMA clinical research materials to Ostfold Hospital Trust at the earliest opportunity, subject to customary regulatory approvals.

"Pharmala was selected after a competitive review of potential manufacturers," said Tor-Morten Kvam at Ostfold Hospital Trust. "Their demonstrated professionalism and understanding of the regulatory and scientific requirements for clinical research made them a strong partner for this study." Researchers like those at Ostfold Hospital Trust can access a tool, offered at the Pharmala website, which provides access to drug product quality information, which researchers can examine directly. Pharmala is confident that it can offer research customers rapid support to convert their clinical trial registrations and IRB approvals to the LaNeo MDMA chemistry, manufacturing and control package.

Pharmala will consider discounts in favour of data sharing where appropriate. Qualified clinical researchers may contact sales@pharmala.ca.

About Pharmala Biotech Holdings Inc.

Pharmala is a biotechnology company focused on the research, development and manufacturing of MDXX class molecules, including MDMA. Pharmala was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. Pharmala is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. Pharmala's research and development unit has completed proof-of-concept research into several IP (intellectual property) families, including ALA-002, its lead drug candidate. Pharmala is a regulatory first organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.

We seek Safe Harbor.